Core Insights - Clearmind Medicine Inc. has successfully completed patient enrollment for the second cohort in its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] - The first cohort showed promising safety and efficacy results, indicating a favorable safety profile and preliminary signs of reduced cravings and withdrawal symptoms [2][4] - The rapid enrollment of the second cohort underscores the commitment of collaborating clinical centers to advance innovative treatments for AUD, a condition with limited effective options affecting millions globally [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property [6] Clinical Trial Details - The multinational Phase I/IIa trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, with dosing for the second cohort expected to start soon [4]

Core Viewpoint - Clearmind Medicine Inc. is implementing a reverse stock split to comply with Nasdaq regulations, which will significantly reduce its outstanding shares while maintaining authorized share capital [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will occur at a ratio of 40 for 1 on December 15, 2025, reducing outstanding shares from approximately 60 million to 1.5 million [1][2]. - The board of directors approved this decision on November 12, 2025, and no fractional shares will be issued; instead, they will be rounded up to the nearest whole share [2]. Group 2: Stock Performance - Following the announcement, CMND's share price dropped 29.92% in after-hours trading, with the stock closing at $0.11 before the announcement, reflecting a decrease of 6.08% [3]. - The current stock price is $2.61, indicating a decrease of approximately 12.14% [3]. - The stock has shown significant volatility, trading between $2.54 and $3.25 on the day of the announcement, with a yearly high of $87.20 and a low of $2.54 [4]. Group 3: Market Capitalization and Trading Volume - CMND's market capitalization is approximately $14.27 million, with a trading volume of 247,625 shares [4].

Core Insights - Clearmind Medicine Inc. has published a review article validating the therapeutic potential of its candidate MEAI in treating alcohol use disorder (AUD) [1][2] - The review highlights MEAI's advantages over classical psychedelics, including a milder subjective experience and lower abuse potential [2] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, particularly AUD [4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents [5] Therapeutic Effects of MEAI - Recreational users typically take MEAI in doses of 1 to 2 mg/kg, reporting positive effects such as reduced desire to consume alcohol within 4 hours [6] - MEAI's receptor interaction profile suggests it may stimulate serotonin release while having a lower risk of abuse compared to other substances like MDMA [6] Adverse Effects - Users of MEAI have not reported serious adverse events, and it is expected to have milder toxicity compared to MDMA due to its receptor interactions [6]

Core Points - Clearmind Medicine Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000, as confirmed by a notification letter from Nasdaq on December 10, 2025 [1][2] - The company is under continued monitoring by Nasdaq for compliance with the Minimum Stockholders' Equity Rule, with potential delisting if compliance is not demonstrated in the next periodic report [2] - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [3] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [4]

Clearmind Medicine Inc. (NASDAQ:CMND) shares fell 29.92% in after-hours trading on Wednesday, dropping to $0.0801.Check out the current price of CMND stock here.The stock of the clinical-stage company closed on Wednesday at $0.11, down 6.08%, according to Benzinga Pro data.Reverse Split Targets Nasdaq Minimum Bid Price RuleClearmind Medicine announced on Wednesday that it will implement a 1-for-40 reverse stock split, effective Dec. 15.The company stated the reverse split is intended to help it regain compl ...

Vancouver, Canada, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-40. The reverse split is being effected as part of the Company’s plan to regain complia ...

Vancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced today that on December 4, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as ...

Core Insights - Clearmind Medicine Inc. has enrolled and dosed the first participant in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with its proprietary drug candidate CMND-100 at Hadassah-University Medical Center in Jerusalem, marking a significant milestone in the trial [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including AUD [1][4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco and evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients [2] - Recent positive results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board support the continuation of the trial [2] Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral therapy targeting Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The company reported positive top-line results from the first cohort of six participants, dosed at prestigious institutions including Johns Hopkins University and Yale University [4] - The independent Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the clinical trial after an interim safety review [5] - Enrollment has commenced at a new clinical site in Israel, Tel Aviv Sourasky Medical Center, enhancing patient recruitment efforts [6] Group 2: Market Context and Impact - AUD affects over 28 million adults in the U.S., incurring societal and economic costs exceeding $249 billion annually, highlighting the need for effective treatments [3] - Current treatment options for AUD are limited in efficacy and accessibility, positioning Clearmind's CMND-100 as a potentially transformative solution [3] Group 3: Company Overview - Clearmind is focused on developing novel neuroplastogen-derived therapeutics to address significant health issues, including AUD [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans for further acquisitions [8]

Core Insights - Clearmind Medicine Inc. (NASDAQ:CMND) experienced a 7.09% increase in pre-market trading, reaching a price of $0.1713 after closing at $0.16, which was a decline of 19.4% on the previous day [1][6]. Group 1: Clinical Trial Developments - The company announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first participant in its multinational Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, which has received approval from the U.S. Food and Drug Administration [2]. - TASMC is part of an expanded trial network that includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center for patient screening and enrollment [3]. - The Phase I/IIa trial is designed to assess the pharmacokinetics, safety, tolerability, and initial efficacy of CMND-100, an oral MEAI-based medication that is not hallucinogenic, with the first cohort's top-line results indicating no significant adverse events [5]. Group 2: Executive Commentary and Stock Performance - Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated that the recruitment of the first patient at TASMC is a significant step that accelerates the global trial [6]. - The company's stock has seen a substantial decline of 88.97% year-to-date, with a 52-week price range of $0.15 to $2.18 and a market capitalization of $5.26 million [6].